outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in hcc
Published 3 years ago • 235 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
2:40
key outcomes of the phase 1b of atezolizumab and bevacizumab for advanced hcc
-
4:03
real-world outcomes of patients with hcc treated with lenvatinib vs. atezolizumab plus bevacizumab
-
0:36
nevena damjanov, md, on the outcomes of combining atezolizumab with bevacizumab in hcc patients
-
3:42
imbrave050: adjuvant atezolizumab with bevacizumab in high-risk hcc
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc
-
1:30
dr. overman on the combination of atezolizumab and bevacizumab in hcc
-
5:30
pivotal data supporting first-line atezolizumab/bevacizumab in unresectable hcc
-
5:12
safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
-
2:13
richard s. finn, md, offers opinion on the role of frontline atezolizumab bevacizumab in hcc
-
1:10
sequencing therapies in the first and second line for patients with hcc
-
3:58
atezolizumab and bevacizumab for upfront unresectable hcc
-
1:04
dr. lee on trial data evaluating the atezolizumab/bevacizumab in unresectable hcc
-
10:42
first-line atezolizumab with bevacizumab for hcc
-
1:06
sequencing treatment options for hcc
-
23:25
dr bharat | role of tecentriq atezolizumab avastin bevacizumab as 1l in unresectable hcc
-
4:14
imbrave150 trial: frontline treatment of advanced hcc
-
4:23
howard hochster, md, on whether atezolizumab bevacizumab regimen is a new standard in care in hcc
-
0:32
will atezolizumab and bevacizumab be the new soc in high-risk hcc?
-
2:01
study evaluates adding radiotherapy to atezolizumab, bevacizumab in hcc